A Phase 3 interventional study of BMN 111 and Placebo in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 24 sites in 7 countries. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.
Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 2 in phase 3, and was the 5th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
By country, each count listing its studies:
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 5 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3
First in 2012; this study’s year is marked. 2 started in 2016.
This study's enrollment of 121 is above the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 74 across the 10 interventional studies, 185 across the 4 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.
This is a Phase 3 randomized, placebo-controlled, double-blind multicenter study with approximately 110 subjects, aged 5 to \< 18 years old. Subjects with documented Achondroplasia confirmed by genetic testing will have been enrolled in Study 111-901 for at least a 6-month period immediately before entering into the 111-301 study. Eligible subjects will be randomly assigned to one of two treatment groups: placebo or BMN 111 at 15 μg/kg. The route of administration is subcutaneous injection and the frequency is daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Have any of the following:
History of any of the following:
Cardiac or vascular disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily subcutaneous injection of 15 micrograms per kilogram BMN111
Drug: BMN 111
Daily subcutaneous injection of placebo
Drug: Placebo
Subcutaneous injection of 15 μg/kg of BMN 111 daily
Also known as: Vosoritide, Modified recombinant human C-type natriuretic peptide
Subcutaneous injection of 15 μg/kg of placebo daily
Change From Baseline in Annualized Growth Velocity (AGV) at Week 52
AGV at a Post-baseline Visit is defined as \[(Height at Post-baseline Visit - Height at Baseline)/(Date of Post-baseline Visit - Date of Baseline Assessment)\] x 365.25 AGV at Baseline is defined as \[(Height at Baseline - last height measurement in Study 111-901 at least 6 months prior to Baseline)/(Date of Baseline Assessment - Date of last height measurement in Study 111-901 at least 6 months prior to Baseline)\] x 365.25
Time frame: At Baseline and Week 52
Change From Baseline in Height Z-score at Week 52
Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased.
Time frame: At baseline and Week 52
Change From Baseline in Upper to Lower Segment Body Ratio at Week 52
Evaluate change from baseline in mean upper:lower segment body ratio in subjects treated with BMN 111 compared with control subjects in the placebo group at 52 weeks
Time frame: At baseline and Week 52
Summary of Subjects Experiencing Adverse Events (AEs) During Treatment
AEs with onset or worsening after the initiation of study drug and up to 30 days after study drug discontinuation were included. serious adverse event (SAE)
Time frame: Up to Week 56
This was a multi-centre study conducted by 24 principal investigators at 24 study centers in 7 countries
| Milestone | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| Started | 60 | 61 |
| Completed | 58 | 61 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
AGV at a Post-baseline Visit is defined as \[(Height at Post-baseline Visit - Height at Baseline)/(Date of Post-baseline Visit - Date of Baseline Assessment)\] x 365.25 AGV at Baseline is defined as \[(Height at Baseline - last height measurement in Study 111-901 at least 6 months prior to Baseline)/(Date of Baseline Assessment - Date of last height measurement in Study 111-901 at least 6 months prior to Baseline)\] x 365.25
| cm/year | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 | 1.71 (1.40 to 2.01) | 0.13 (-0.18 to 0.45) |
Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased.
| Z-Score | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| Change From Baseline in Height Z-score at Week 52 | 0.27 (0.18 to 0.36) | -0.01 (-0.10 to 0.09) |
Evaluate change from baseline in mean upper:lower segment body ratio in subjects treated with BMN 111 compared with control subjects in the placebo group at 52 weeks
| Ratio | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| Change From Baseline in Upper to Lower Segment Body Ratio at Week 52 | -0.03 (-0.06 to 0.00) | -0.02 (-0.05 to 0.01) |
AEs with onset or worsening after the initiation of study drug and up to 30 days after study drug discontinuation were included. serious adverse event (SAE)
| participants | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| Subjects with any AE | 59 | 60 |
| Subjects with any SAE | 3 | 4 |
| Subjects with any treatment-related AE | 53 | 51 |
| Subjects who died | 0 | 0 |
Collected over Up to Week 56. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMN 111 - 15 μg/kg | 0/60 (0%) | 3/60 (5%) | 59/60 (98.3%) |
| Placebo | 0/61 (0%) | 4/61 (6.6%) | 60/61 (98.4%) |
| Event | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| InfluenzaInfections and infestations | 1/60 | 0/61 |
| Radius fractureInjury, poisoning and procedural complications | 1/60 | 0/61 |
| Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders | 1/60 | 1/61 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 1/60 | 0/61 |
| AppendicitisInfections and infestations | 0/60 | 1/61 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/60 | 1/61 |
| Intracranial pressure increasedNervous system disorders | 0/60 | 1/61 |
| Spinal cord compressionNervous system disorders | 0/60 | 1/61 |
| Event | BMN 111 - 15 μg/kg | Placebo |
|---|---|---|
| Injection site reactionGeneral disorders | 44/60 | 29/61 |
| Injection site erythemaGeneral disorders | 41/60 | 40/61 |
| Injection site swellingGeneral disorders | 23/60 | 6/61 |
| NasopharyngitisInfections and infestations | 16/60 | 18/61 |
| VomitingGastrointestinal disorders | 16/60 | 12/61 |
| HeadacheNervous system disorders | 14/60 | 16/61 |
| PyrexiaGeneral disorders | 10/60 | 13/61 |
| Upper respiratory tract infectionInfections and infestations | 8/60 | 10/61 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/60 | 4/61 |
| Injection site urticariaGeneral disorders | 8/60 | 2/61 |
Analysis were performed on the Full Analysis Set (FAS) which included all randomized subjects with a signed informed consent.
| Age, Continuous(years) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Mean | 8.35 ± 2.43 | 9.06 ± 2.47 | 8.71 ± 2.47 |
| Sex: Female, Male(Participants) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Female | 29 | 28 | 57 |
| Male | 31 | 33 | 64 |
| Ethnicity (NIH/OMB)(Participants) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 6 | 7 |
| Not Hispanic or Latino | 59 | 55 | 114 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Race — White | 45 | 41 | 86 |
| Race — Asian-Other | 7 | 9 | 16 |
| Race — Asian-Japanese | 3 | 4 | 7 |
| Race — Multiple | 2 | 5 | 7 |
| Race — Black or African American | 3 | 2 | 5 |
| Annualized Growth Velocity (AGV)(cm/year) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Mean | 4.26 ± 1.53 | 4.06 ± 1.20 | 4.16 ± 1.37 |
| Height Z-Score(Z-score) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Mean | -5.13 ± 1.11 | -5.14 ± 1.07 | -5.13 ± 1.09 |
| Upper to Lower Body Segment Ratio(Ratio) | BMN 111 - 15 μg/kg | Placebo | Total |
|---|---|---|---|
| Mean | 1.98 ± 0.20 | 2.01 ± 0.21 | 2.00 ± 0.20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2016 to primary completion in Oct 2019, 34 months.
Results were first posted in Mar 2022, 2 years 4 months after primary completion. A results delay was requested in May 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vosoritide